A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and tolerability of ascending doses of SB
9200 given for up to 14 days to subjects with chronic Hepatitis C infection.
Phase:
Phase 1
Details
Lead Sponsor:
INC Research Syneos Health
Collaborators:
F-star Therapeutics, Inc. Spring Bank Pharmaceuticals, Inc.